Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMGQRON)

Drug Name
BETULIN Drug Info
Synonyms
Betulin; 473-98-3; Betulinol; Betuline; Trochol; Lup-20(29)-ene-3b,28-diol; Betulol; Lup-20(29)-ene-3beta,28-diol; UNII-6W70HN7X7O; NSC 4644; C30H50O2; EINECS 207-475-5; Lup-20(30)-ene-3beta,28-diol; AI3-62999; CHEBI:3086; 6W70HN7X7O; Lup-20(29)-ene-3,28-diol, (3beta)-; (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-(Hydroxymethyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysen-9-ol; Betulinic alcohol; lup-20(29)-ene-3 beta,28-diol
Cross-matching ID
PubChem CID
72326
ChEBI ID
CHEMBL23236
CAS Number
CAS 473-98-3
TTD Drug ID
D05KJY

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Mineral absorption 2.30 0.00e+0 48/60 (80%) MT1F;MT1H;MT1X;...
Th1 and Th2 cell differentiation -1.68 2.02e-2 80/92 (86.96%) MAPK10;TYK2;TBX21;...
Bacterial invasion of epithelial cells -1.68 2.04e-2 59/77 (76.62%) DNM2;HCLS1;PXN;...
T cell receptor signaling pathway -1.68 2.10e-2 93/104 (89.42%) AKT2;NCK2;MAPK10;...
ErbB signaling pathway -1.70 1.99e-2 79/85 (92.94%) AKT2;NCK2;MAPK10;...
Focal adhesion -1.70 2.06e-2 180/201 (89.55%) TLN1;RAC2;FN1;...
Fatty acid elongation -1.71 2.04e-2 19/27 (70.37%) ACOT7;HACD1;HACD3;...
Th17 cell differentiation -1.73 1.66e-2 95/107 (88.79%) CD3D;RORA;IL6R;...
TNF signaling pathway -1.73 1.67e-2 103/112 (91.96%) CCL20;TRAF3;CREB1;...
Type I diabetes mellitus -1.73 1.69e-2 38/43 (88.37%) HLA-A;HLA-G;HLA-E;...
IL-17 signaling pathway -1.73 1.70e-2 84/94 (89.36%) HSP90AB1;ELAVL1;CCL20;...
Hematopoietic cell lineage -1.73 1.72e-2 90/99 (90.91%) CD37;CSF1R;TFRC;...
Endocytosis -1.73 1.79e-2 198/252 (78.57%) CBLB;PIP5K1C;HLA-G;...
Graft-versus-host disease -1.75 1.64e-2 32/42 (76.19%) HLA-A;HLA-G;HLA-E;...
Inflammatory bowel disease -1.75 1.65e-2 58/65 (89.23%) IL21;HLA-DPA1;IL1A;...
PD-L1 expression and PD-1 checkpoint pathway in cancer -1.75 1.73e-2 79/89 (88.76%) MAP3K3;CSNK2A1;AKT2;...
VEGF signaling pathway -1.75 1.82e-2 50/59 (84.75%) AKT2;PIK3CB;PLCG2;...
Malaria -1.76 1.85e-2 44/50 (88%) GYPA;ACKR1;VCAM1;...
Neutrophil extracellular trap formation -1.76 1.88e-2 101/189 (53.44%) SLC25A5;ITGA2B;ELANE;...
Leishmaniasis -1.76 1.91e-2 67/77 (87.01%) JAK2;MAPK11;MAPK14;...
Intestinal immune network for IgA production -1.77 2.03e-2 38/48 (79.17%) ITGB7;HLA-DPA1;ICOS;...
Fc gamma R-mediated phagocytosis -1.84 1.30e-2 79/97 (81.44%) FCGR2A;AKT2;PIP5K1A;...
Toxoplasmosis -1.87 8.67e-3 103/112 (91.96%) JAK1;HLA-DPA1;CD40LG;...
Osteoclast differentiation -1.89 6.50e-3 117/127 (92.13%) FCGR2A;LILRA5;AKT2;...
Ferroptosis -1.90 3.71e-3 36/41 (87.8%) ACSL3;GCLC;GPX4;...
Collecting duct acid secretion -1.92 4.33e-3 22/27 (81.48%) ATP6V0A1;ATP6V0E2;ATP6V0D1;...
Toll-like receptor signaling pathway -1.96 2.60e-3 94/104 (90.38%) CD86;TLR7;IKBKB;...
NF-kappa B signaling pathway -2.00 0.00e+0 90/104 (86.54%) ICAM1;BIRC3;CD14;...
Phagosome -2.03 0.00e+0 118/152 (77.63%) ITGAM;TUBB1;FCGR2B;...
Asthma -2.21 0.00e+0 25/31 (80.65%) HLA-DPA1;CD40LG;HLA-DOB;...
Rheumatoid arthritis -2.25 0.00e+0 78/93 (83.87%) ATP6V1F;CCL20;HLA-DPA1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.004uM - 4uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.004uM - 4uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.004uM - 4uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.004uM - 4uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.004uM - 4uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.004uM - 4uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.004uM - 4uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.004uM - 4uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.004uM - 4uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.004uM - 4uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.004uM - 4uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.004uM - 4uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.004uM - 4uM 24H